

# Maddalena Sansovini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6080079/publications.pdf>

Version: 2024-02-01

34  
papers

2,131  
citations

361413

20  
h-index

377865

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

2017  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with <sup>90</sup> Y-DOTATOC and <sup>177</sup> Lu-DOTATATE: the role of associated risk factors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1847-1856.	6.4	353
2	Peptide receptor radionuclide therapy with <sup>177</sup> Lu-DOTATATE: the IEO phase I-II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2125-2135.	6.4	349
3	Transvaginal evisceration after hysterectomy: Is vaginal cuff closure associated with a reduced risk?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 125, 134-138.	1.1	130
4	Role of <sup>18</sup> F-FDG PET/CT in patients treated with <sup>177</sup> Lu-DOTATATE for advanced differentiated neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 881-888.	6.4	123
5	Peptide receptor radionuclide therapy with <sup>90</sup> Y-DOTATOC in recurrent meningioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1407-1416.	6.4	121
6	Treatment with the Radiolabelled Somatostatin Analog <sup>177</sup> Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2013, 97, 347-354.	2.5	104
7	<sup>177</sup> Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1845-1851.	6.4	103
8	<sup>18</sup> F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. <i>European Journal of Surgical Oncology</i> , 2005, 31, 792-797.	1.0	98
9	Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with <sup>177</sup> Lu-D OTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 490-499.	6.4	95
10	Peptide receptor radionuclide therapy with <sup>177</sup> Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and <sup>18</sup> F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1040-1046.	6.4	77
11	Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup> Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL). <i>Hormone and Metabolic Research</i> , 2012, 44, 411-414.	1.5	71
12	Feasibility and utility of re-treatment with <sup>177</sup> Lu-DOTATATE in GEP-NENs relapsed after treatment with <sup>90</sup> Y-DOTATOC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1955-1963.	6.4	62
13	Age-Related Structural and Metabolic Changes in the Pelvic Reproductive End Organs. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 173-184.	4.6	61
14	Investigation of receptor radionuclide therapy with <sup>177</sup> Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 923-930.	6.4	56
15	Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 551-557.	2.0	37
16	Dosimetry and safety of <sup>177</sup> Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3008-3017.	6.4	37
17	The Effects of Aging on Testicular Volume and Glucose Metabolism: an Investigation with Ultrasonography and FDG-PET. <i>Molecular Imaging and Biology</i> , 2011, 13, 391-398.	2.6	34
18	Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with <sup>177</sup> Lu-DOTATATE and <sup>90</sup> Y-DOTATOC. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 659-665.	1.0	33

#	ARTICLE	IF	CITATIONS
19	Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3260-3267.	6.4	29
20	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. <i>European Journal of Cancer</i> , 2022, 162, 221-236.	2.8	22
21	177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 152-160.	6.4	20
22	Peptide Receptor Radionuclide Therapy in a Case of Multiple Spinal Canal and Cranial Paragangliomas. <i>Journal of Clinical Oncology</i> , 2011, 29, e171-e174.	1.6	19
23	The Role of Dosimetry in the High Activity 90Y-ibritumomab Tiuxetan Regimens: Two Cases of Abnormal Biodistribution. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 271-275.	1.0	17
24	Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2021, 14, 476.	3.8	16
25	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	6.4	13
26	<sup>68</sup> Ga-DOTA-D <sup>0</sup> TA <sup>0</sup> T <sup>3</sup> yr <sup>3</sup> octreotide (<sup>DOTATOC</sup>) positron emission tomography (<sup>PET</sup>)/<sup>CT</sup> in five cases of ectopic adrenocorticotropin-secreting tumours. <i>Clinical Endocrinology</i> , 2014, 81, 152-153.	2.4	11
27	Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin). <i>Nuclear Medicine and Biology</i> , 2010, 37, 85-93.	0.6	9
28	A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	8
29	Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. <i>Cancers</i> , 2022, 14, 3231.	3.7	5
30	A case of metachronous double primary neuroendocrine cancer in pancreas/ileum and uterine cervix. <i>Upsala Journal of Medical Sciences</i> , 2012, 117, 453-456.	0.9	4
31	Development of sentinel node localization and ROLL in breast cancer in Europe. <i>Clinical and Translational Imaging</i> , 2015, 3, 171-178.	2.1	2
32	Theragnostic in neuroendocrine tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.7	2
33	Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1777-1778.	6.4	1
34	Management of Pancreatic and Duodenal Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 153-167.	0.1	0